Show simple item record

dc.contributor.authorMangino, M
dc.contributor.authorCecelja, M
dc.contributor.authorMenni, C
dc.contributor.authorTsai, P-C
dc.contributor.authorYuan, W
dc.contributor.authorSmall, K
dc.contributor.authorBell, J
dc.contributor.authorMitchell, GF
dc.contributor.authorChowienczyk, P
dc.contributor.authorSpector, TD
dc.date.accessioned2018-07-05T09:12:13Z
dc.date.issued2016-01-01
dc.identifierhttp://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2016&issue=01000&article=00013&type=abstract
dc.identifier.citationJOURNAL OF HYPERTENSION, 2016, 34 (1), pp. 79 - 87
dc.identifier.issn0263-6352
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1985
dc.description.abstractBackground: Carotid-femoral pulse wave velocity (PWV) is an important measure of arterial stiffness, which is an independent predictor of cardiovascular morbidity and mortality. In this study, we used an integrated genetic, epigenetic and transcriptomics approach to uncover novel molecular mechanisms contributing to PWV. Methods and results: We measured PWV in 1505 healthy twins of European descendent. A genomewide association analysis was performed using standardized residual of the inverse of PWV. We identified one single-nucleotide polymorphism (rs7164338) in the calcium and integrin-binding protein-2 (CIB2) gene on chromosome 15q25.1 associated with PWV [beta = -0.359, standard error (SE) = 0.07, P = 4.8 x 10(-8)]. The same variant was also associated with increased CIB2 expression in leucocytes (beta = 0.034, SE = 0.008, P = 4.95 x 10(-5)) and skin (beta = 0.072, SE = 0.01, P = 2.35 x 10(-9)) and with hypomethylation of the gene promoter (beta = -.899, SE = 0.098, P = 3.63 x 10(-20)). Conclusion: Our data indicate that reduced methylation of the CIB2 promoter in individuals carrying rs7164338 may lead to increased CIB2 expression. Given that CIB2 is thought to regulate intracellular calcium levels, an increase in protein levels may prevent the accumulation of serum calcium and phosphate, ultimately slowing down the process of vascular calcification. This study shows the power of integrating multiple omics to discover novel cardiovascular mechanisms.
dc.format.extent79 - 87
dc.languageeng
dc.language.isoeng
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectarterial stiffness arteriosclerosis association calcium and integrin-binding protein-2 pulse wave velocity vascular calcification GENOME-WIDE ASSOCIATION CHRONIC KIDNEY-DISEASE ALL-CAUSE MORTALITY ARTERIAL STIFFNESS CARDIOVASCULAR EVENTS BLOOD-PRESSURE RACIAL-DIFFERENCES AORTIC STIFFNESS CALCIFICATION RISK
dc.titleIntegrated multiomics approach identifies calcium and integrin-binding protein-2 as a novel gene for pulse wave velocity
dc.typeJournal Article
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJOURNAL OF HYPERTENSION
pubs.issue1
pubs.notesISI Document Delivery No.: DK9CT Times Cited: 1 Cited Reference Count: 47 Mangino, Massimo Cecelja, Marina Menni, Cristina Tsai, Pei-Chien Yuan, Wei Small, Kerrin Bell, Jordana Mitchell, Gary F. Consortium, AortaGen Chowienczyk, Phillip Spector, Tim D. Wellcome Trust; European Community's Seventh Framework Programme (FP7); National Institute for Health Research (NIHR) BioResource Clinical Research Facility; Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also received support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. SNP genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR. 1 LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA J HYPERTENS public Background: Carotid-femoral pulse wave velocity (PWV) is an important measure of arterial stiffness, which is an independent predictor of cardiovascular morbidity and mortality. In this study, we used an integrated genetic, epigenetic and transcriptomics approach to uncover novel molecular mechanisms contributing to PWV. Methods and results: We measured PWV in 1505 healthy twins of European descendent. A genomewide association analysis was performed using standardized residual of the inverse of PWV. We identified one single-nucleotide polymorphism (rs7164338) in the calcium and integrin-binding protein-2 (CIB2) gene on chromosome 15q25.1 associated with PWV [beta = -0.359, standard error (SE) = 0.07, P = 4.8 x 10(-8)]. The same variant was also associated with increased CIB2 expression in leucocytes (beta = 0.034, SE = 0.008, P = 4.95 x 10(-5)) and skin (beta = 0.072, SE = 0.01, P = 2.35 x 10(-9)) and with hypomethylation of the gene promoter (beta = -.899, SE = 0.098, P = 3.63 x 10(-20)). Conclusion: Our data indicate that reduced methylation of the CIB2 promoter in individuals carrying rs7164338 may lead to increased CIB2 expression. Given that CIB2 is thought to regulate intracellular calcium levels, an increase in protein levels may prevent the accumulation of serum calcium and phosphate, ultimately slowing down the process of vascular calcification. This study shows the power of integrating multiple omics to discover novel cardiovascular mechanisms.
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.volume34
pubs.embargo.termsNot known
icr.researchteamCancer Biomarkers
dc.contributor.icrauthorYuan, Wei


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0